- Trial phase
- Preclinical
- Time to market
- PRX012-TfR is in preclinical development with no disclosed IND filing or clinical trial start date. If preclinical work proceeds successfully, a Phase 1 trial could begin in 2027-2028, putting potential approval many years away (likely 2030+).
- Why 2/10
- PRX012-TfR is a preclinical-stage program with no scheduled PDUFA date, pivotal readout, or other hard binary catalyst in the next ~12 months. The program is a small part of Prothena's broader pipeline, which is dominated by partnered late-stage programs (prasinezumab, coramitug, moponetug). ImpactScore is set at 2: preclinical, minor program within a larger pipeline, no near-term catalyst.
PRX012-TfR is a preclinical program with no near-term binary catalyst. Watch for any partnership announcement or IND filing as the next potential value-inflection point, but the program is likely years away from clinical data. Prothena's nearer-term value drivers are the partnered moponetug (Phase 2 readout 1H 2027) and prasinezumab/coramitug Phase 3 programs.
Price Chart
Executive Summary
PRX012-TfR is a preclinical-stage bispecific antibody program from Prothena Corporation (NASDAQ: PRTA) that combines an anti-amyloid beta component with transferrin receptor (TfR) targeting to improve brain delivery for Alzheimer's disease. It is the next-generation evolution of PRX012, a once-monthly subcutaneous anti-amyloid antibody that completed Phase 1 ASCENT testing in August 2025 but showed higher-than-desired rates of brain swelling (ARIA), leading Prothena to label the profile 'non-competitive' and seek partnerships. Prothena confirmed in early 2026 that it is 'actively advancing' PRX012-TfR in preclinical development, but the program has no disclosed IND filing, clinical trial start date, or near-term catalyst. PRX012-TfR represents a small, early-stage component of Prothena's pipeline, which is dominated by partnered late-stage programs (prasinezumab with Roche, coramitug with Novo Nordisk, moponetug with BMS).
How It Works
PRX012-TfR is a preclinical bispecific antibody designed to treat Alzheimer's disease. One part of the antibody targets and helps clear amyloid beta plaques (protein clumps in the brain that are a hallmark of Alzheimer's). The other part binds to the transferrin receptor (TfR), a protein on the blood-brain barrier that acts like a ferry, helping the antibody cross from the bloodstream into the brain more efficiently. This 'brain-shuttle' approach aims to deliver more drug to the target with potentially lower doses and fewer side effects like brain swelling (ARIA) that have plagued other anti-amyloid antibodies.
Trial Status
PRX012-TfR is in preclinical development. Its parent molecule PRX012 completed a Phase 1 ASCENT clinical program in early symptomatic Alzheimer's disease patients in August 2025, establishing proof-of-mechanism as a once-monthly subcutaneous anti-amyloid beta antibody. However, the Phase 1 results showed brain swelling (ARIA) rates that Prothena described as 'non-competitive' versus approved therapies. Prothena subsequently announced plans to explore partnership opportunities for both PRX012 and the preclinical PRX012-TfR program.
The Two-Sided Case
Upcoming Catalysts
- Potential partnership announcement for PRX012 or PRX012-TfR
- Possible IND filing for PRX012-TfR (no date disclosed)
- Moponetug (PRX005) Phase 2 TargetTau-1 data readout expected 1H 2027 (partnered with BMS)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PROTHENA CORP PUBLIC LTD CO 8-K PRTA ·Originating report